Skip to main content

Corvus Pharmaceuticals, Inc.

CRVS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001626971

No open-market purchases or sales by Corvus Pharmaceuticals, Inc. insiders were filed in the last 90 days; 173 institutions reported holding it in 13F filings for Q2 2026, worth $1.06B in total; no superinvestor holds it.

Superinvestors holding CRVS, Q2 2026

See all superinvestors

No superinvestor reported holding CRVS in Q2 2026.